CN104853774B - Il-20拮抗剂用于治疗肝脏疾病 - Google Patents
Il-20拮抗剂用于治疗肝脏疾病 Download PDFInfo
- Publication number
- CN104853774B CN104853774B CN201380051640.9A CN201380051640A CN104853774B CN 104853774 B CN104853774 B CN 104853774B CN 201380051640 A CN201380051640 A CN 201380051640A CN 104853774 B CN104853774 B CN 104853774B
- Authority
- CN
- China
- Prior art keywords
- antibody
- purposes
- liver
- human
- mab7e
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (16)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/568,633 | 2012-08-07 | ||
US13/568,633 US8603470B1 (en) | 2012-08-07 | 2012-08-07 | Use of IL-20 antagonists for treating liver diseases |
PCT/US2013/053775 WO2014025767A1 (en) | 2012-08-07 | 2013-08-06 | Use of il-20 antagonists for treating liver diseases |
Publications (3)
Publication Number | Publication Date |
---|---|
CN104853774A CN104853774A (zh) | 2015-08-19 |
CN104853774A8 CN104853774A8 (zh) | 2016-08-17 |
CN104853774B true CN104853774B (zh) | 2018-11-02 |
Family
ID=49681491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380051640.9A Active CN104853774B (zh) | 2012-08-07 | 2013-08-06 | Il-20拮抗剂用于治疗肝脏疾病 |
Country Status (4)
Country | Link |
---|---|
US (2) | US8603470B1 (zh) |
EP (1) | EP2882456B1 (zh) |
CN (1) | CN104853774B (zh) |
WO (1) | WO2014025767A1 (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110039218A (ko) * | 2008-06-30 | 2011-04-15 | 노보 노르디스크 에이/에스 | 항-인간 인터루킨-20 항체 |
EP3708190A1 (en) | 2010-02-26 | 2020-09-16 | Novo Nordisk A/S | Stable antibody containing compositions |
US20130136733A1 (en) | 2010-05-28 | 2013-05-30 | Novo Nordisk A/S | Stable Multi-Dose Compositions Comprising an Antibody and a Preservative |
US8597647B1 (en) | 2012-05-22 | 2013-12-03 | National Cheng Kung University | Humanized anti-IL-20 antibody and uses thereof |
US8603470B1 (en) | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
WO2021086997A1 (en) * | 2019-10-28 | 2021-05-06 | LBL Biotechnology Inc. | Treating tissue fibrosis and/or injury and-or organ failure with interleukin 24 or interleukin 20 antagonist |
US11661450B2 (en) | 2020-04-22 | 2023-05-30 | LBL Biotechnology Inc. | Combination therapy using an IL-20 antagonist and an immune checkpoint inhibitor |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060142550A1 (en) * | 2003-05-23 | 2006-06-29 | Chi-Mei Medical Center | Antibodies to interleukin-20 and method for inhibiting interleukin-20 induced cell proliferation |
US20110064731A1 (en) * | 2009-08-31 | 2011-03-17 | National Cheng Kung University | Use of IL-20 Antagonists for Treating Rheumatoid Arthritis and Osteoporosis |
CN102281898A (zh) * | 2008-10-07 | 2011-12-14 | 成功大学 | Il-20拮抗剂在治疗类风湿性关节炎和骨质疏松症中的应用 |
Family Cites Families (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
WO1995013796A1 (en) | 1993-11-16 | 1995-05-26 | Depotech Corporation | Vesicles with controlled release of actives |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0832980B1 (en) | 1989-01-23 | 2002-06-19 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
WO1990011092A1 (en) | 1989-03-21 | 1990-10-04 | Vical, Inc. | Expression of exogenous polynucleotide sequences in a vertebrate |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
WO1991002805A2 (en) | 1989-08-18 | 1991-03-07 | Viagene, Inc. | Recombinant retroviruses delivering vector constructs to target cells |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5399676A (en) | 1989-10-23 | 1995-03-21 | Gilead Sciences | Oligonucleotides with inverted polarity |
US5321131A (en) | 1990-03-08 | 1994-06-14 | Hybridon, Inc. | Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling |
NZ237464A (en) | 1990-03-21 | 1995-02-24 | Depotech Corp | Liposomes with at least two separate chambers encapsulating two separate biologically active substances |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
DK261490D0 (da) | 1990-10-31 | 1990-10-31 | Novo Nordisk As | New pharmaceutical compound |
WO1993003769A1 (en) | 1991-08-20 | 1993-03-04 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES | Adenovirus mediated transfer of genes to the gastrointestinal tract |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
US5792608A (en) | 1991-12-12 | 1998-08-11 | Gilead Sciences, Inc. | Nuclease stable and binding competent oligomers and methods for their use |
FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1993025234A1 (en) | 1992-06-08 | 1993-12-23 | The Regents Of The University Of California | Methods and compositions for targeting specific tissue |
JPH09507741A (ja) | 1992-06-10 | 1997-08-12 | アメリカ合衆国 | ヒト血清による不活性化に耐性のあるベクター粒子 |
GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
EP0673431A1 (en) | 1992-12-03 | 1995-09-27 | Genzyme Corporation | Gene therapy for cystic fibrosis |
US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
PT695169E (pt) | 1993-04-22 | 2003-04-30 | Skyepharma Inc | Lipossomas multivesiculares de ciclodextrina encapsulando compostos farmacologicos e metodos para a sua utilizacao |
JP3532566B2 (ja) | 1993-06-24 | 2004-05-31 | エル. グラハム,フランク | 遺伝子治療のためのアデノウイルスベクター |
US5888510A (en) | 1993-07-21 | 1999-03-30 | Chugai Seiyaku Kabushiki Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
DE69435233D1 (de) | 1993-09-15 | 2009-10-08 | Novartis Vaccines & Diagnostic | Rekombinante Alphavirus Vektoren |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
ATE437232T1 (de) | 1993-10-25 | 2009-08-15 | Canji Inc | Rekombinanter adenoviren-vektor und verfahren zur verwendung |
US5625050A (en) | 1994-03-31 | 1997-04-29 | Amgen Inc. | Modified oligonucleotides and intermediates useful in nucleic acid therapeutics |
ATE381624T1 (de) | 1994-05-09 | 2008-01-15 | Oxford Biomedica Ltd | Retrovirale vektoren mit verminderter rekombinationsrate |
AU4594996A (en) | 1994-11-30 | 1996-06-19 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
DE69739286D1 (de) | 1996-05-06 | 2009-04-16 | Oxford Biomedica Ltd | Rekombinationsunfähige retrovirale vektoren |
US6001311A (en) | 1997-02-05 | 1999-12-14 | Protogene Laboratories, Inc. | Apparatus for diverse chemical synthesis using two-dimensional array |
US6649779B2 (en) | 1997-05-02 | 2003-11-18 | Wyeth | Estrenes |
AU8571198A (en) | 1997-07-16 | 1999-02-10 | Human Genome Sciences, Inc. | Interleukin-20 |
US6576743B1 (en) | 1997-11-26 | 2003-06-10 | Zymogenetics, Inc. | Mammalian cytokine-like polypeptide-10 |
EP1424393A3 (en) | 1997-11-26 | 2004-06-09 | Zymogenetics Inc | Mammalian cytokine-like polypeptide-10 |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
WO2000053211A2 (en) | 1999-03-09 | 2000-09-14 | University Of Southern California | Method of promoting myocyte proliferation and myocardial tissue repair |
US20030148955A1 (en) | 1999-04-19 | 2003-08-07 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
US7122632B2 (en) | 1999-12-23 | 2006-10-17 | Zymogenetics, Inc. | Soluble Interleukin-20 receptor |
US6610286B2 (en) | 1999-12-23 | 2003-08-26 | Zymogenetics, Inc. | Method for treating inflammation using soluble receptors to interleukin-20 |
DK1616575T3 (da) | 1999-12-23 | 2012-09-10 | Zymogenetics Inc | Fremgangsmåde til behandling af inflammation |
IL155002A0 (en) | 2000-10-12 | 2003-10-31 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
US20050143333A1 (en) | 2001-05-18 | 2005-06-30 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA) |
AU2002330031B2 (en) | 2001-09-21 | 2007-07-05 | Merck & Co., Inc. | Androstanes as androgen receptor modulators |
CA2465499A1 (en) | 2001-11-08 | 2003-05-15 | Merck & Co., Inc. | Compositions and methods for treating osteoporosis |
WO2003051384A1 (en) | 2001-12-17 | 2003-06-26 | Zymogenetics, Inc. | Method for treating cervical cancer |
US20040009168A1 (en) | 2002-04-05 | 2004-01-15 | Elizabet Kaisheva | Multidose antibody formulation |
US20040191243A1 (en) | 2002-12-13 | 2004-09-30 | Bei Chen | System and method for stabilizing antibodies with histidine |
EA009026B1 (ru) | 2003-03-24 | 2007-10-26 | Займоджинетикс, Инк. | Антитела против il-22ra, их партнеры по связыванию и способы их применения при воспалениях |
RU2332986C2 (ru) | 2003-04-04 | 2008-09-10 | Дженентек, Инк. | Высококонцентрированные композиции антител и белков |
JP2007501813A (ja) | 2003-08-08 | 2007-02-01 | ノボ ノルディスク アクティーゼルスカブ | 新生血管形成と関連した症状を治療および診断するためのインターロイキン−20 |
ATE447587T1 (de) | 2003-11-21 | 2009-11-15 | Zymogenetics Inc | Anti-il-20-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen |
MX2007004770A (es) | 2004-10-22 | 2007-11-22 | Zymogenetics Inc | Anticuerpos anti-il-22ra y moleculas y metodos para usarlos en inflamacion. |
EP2192132A3 (en) | 2005-02-08 | 2010-08-18 | ZymoGenetics, Inc. | Anti-IL-20, anti-IL22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation |
AU2006295340B2 (en) | 2005-08-05 | 2010-11-11 | Amgen Inc. | Stable aqueous protein or antibody pharmaceutical formulations and their preparation |
WO2007081465A2 (en) | 2005-12-09 | 2007-07-19 | Chi-Mei Medical Center | Antibodies to interleukin-20 and method for inhibiting interleukin-20 induced cell proliferation |
JP5829004B2 (ja) | 2006-06-30 | 2015-12-09 | ノボ・ノルデイスク・エー/エス | 抗nkg2a抗体とその使用 |
ATE493161T1 (de) | 2006-07-15 | 2011-01-15 | Novo Nordisk As | Medizinisches abgabesystem mit asymmetrischen kodiervorrichtungen |
KR20090069330A (ko) | 2006-10-12 | 2009-06-30 | 와이어쓰 | 유백광/응집체를 감소시키기 위한 항체 용액 중의 이온 강도의 변화 |
PE20081610A1 (es) | 2007-01-09 | 2008-12-09 | Wyeth Corp | Formulaciones de anticuerpos anti-il-13 y usos de los mismos |
US7611705B2 (en) | 2007-06-15 | 2009-11-03 | National Cheng Kung University | Anti-IL-20 antibody and its use in treating IL-20 associated inflammatory diseases |
EP2050458A1 (en) | 2007-10-17 | 2009-04-22 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL24 for inducing hyperproliferative or autoimmune cell death |
PL2222706T5 (pl) | 2007-12-14 | 2017-09-29 | Novo Nordisk As | Przeciwciała przeciwko ludzkiemu NKG2D i ich zastosowania |
US8268972B2 (en) | 2008-02-20 | 2012-09-18 | G2 Inflammation Pty Ltd | Humanized anti-C5aR antibodies |
PT2296672E (pt) * | 2008-06-11 | 2016-01-22 | Fresenius Medical Care De Gmbh | Meio condicionado de células progenitoras de fígado |
TWI451876B (zh) | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
KR20110039218A (ko) | 2008-06-30 | 2011-04-15 | 노보 노르디스크 에이/에스 | 항-인간 인터루킨-20 항체 |
US7837994B2 (en) | 2008-10-07 | 2010-11-23 | National Cheng Kung University | Use of anti-IL-20 antibody for treating osteoporosis |
US8012478B2 (en) | 2008-10-07 | 2011-09-06 | National Cheng Kung University | Use of anti-IL-20 antibody for treating stroke |
CN102325795B (zh) | 2008-12-22 | 2015-03-25 | 诺沃—诺迪斯克有限公司 | 针对组织因子途径抑制剂的抗体 |
EP3708190A1 (en) | 2010-02-26 | 2020-09-16 | Novo Nordisk A/S | Stable antibody containing compositions |
US9127066B2 (en) | 2010-04-16 | 2015-09-08 | National Cheng Kung University | Methods for treating osteoporosis with anti-IL-20 receptor antibodies |
US20130136733A1 (en) | 2010-05-28 | 2013-05-30 | Novo Nordisk A/S | Stable Multi-Dose Compositions Comprising an Antibody and a Preservative |
US20110305699A1 (en) | 2010-06-15 | 2011-12-15 | National Cheng Kung University | Treating Oral Cancer with Anti-IL-20 Antibody |
US8535674B2 (en) | 2010-06-15 | 2013-09-17 | National Cheng Kung University | Treating breast cancer and inhibiting cancer-associated bone loss with anti-IL-20 antibody |
US8603470B1 (en) | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
-
2012
- 2012-08-07 US US13/568,633 patent/US8603470B1/en active Active
-
2013
- 2013-08-06 EP EP13828706.5A patent/EP2882456B1/en not_active Not-in-force
- 2013-08-06 WO PCT/US2013/053775 patent/WO2014025767A1/en active Application Filing
- 2013-08-06 CN CN201380051640.9A patent/CN104853774B/zh active Active
- 2013-10-30 US US14/067,034 patent/US9365652B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060142550A1 (en) * | 2003-05-23 | 2006-06-29 | Chi-Mei Medical Center | Antibodies to interleukin-20 and method for inhibiting interleukin-20 induced cell proliferation |
CN102281898A (zh) * | 2008-10-07 | 2011-12-14 | 成功大学 | Il-20拮抗剂在治疗类风湿性关节炎和骨质疏松症中的应用 |
US20110064731A1 (en) * | 2009-08-31 | 2011-03-17 | National Cheng Kung University | Use of IL-20 Antagonists for Treating Rheumatoid Arthritis and Osteoporosis |
Non-Patent Citations (3)
Title |
---|
Chi-Chen Wei et al..IL-20:biological functions and clinical implications.《Journal of Biomedical Science》.2006,第601-612页. * |
Ursula Maria et al..The murine liver is a potential target organ for IL-19,IL-20 and IL-24:Type I interferons and LPS regulate the expression of IL-20R2.《Journal of Hepatology》.2007,第257-265页. * |
陈新.肝纤维化的治疗现状.《人民军医》.2009,第52卷(第9期),第613-615页. * |
Also Published As
Publication number | Publication date |
---|---|
US9365652B2 (en) | 2016-06-14 |
EP2882456A1 (en) | 2015-06-17 |
US8603470B1 (en) | 2013-12-10 |
CN104853774A (zh) | 2015-08-19 |
WO2014025767A1 (en) | 2014-02-13 |
CN104853774A8 (zh) | 2016-08-17 |
US20140120094A1 (en) | 2014-05-01 |
EP2882456A4 (en) | 2016-06-08 |
EP2882456B1 (en) | 2019-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104853774B (zh) | Il-20拮抗剂用于治疗肝脏疾病 | |
CN1997394B (zh) | 含有用于调节血管发育的egfl7拮抗剂的组合物及方法 | |
CN107007833A (zh) | 抗il‑36r抗体 | |
CN102281898B (zh) | Il-20拮抗剂在治疗类风湿性关节炎和骨质疏松症中的应用 | |
CN107613974A (zh) | 抗‑met抗体及其使用方法 | |
CN102176914B (zh) | 用于诊断和治疗癌症的vhz | |
CN106687124A (zh) | 并用il‑18与分子靶向抗体的癌治疗药 | |
CN106573976A (zh) | 抗cd84抗体、包含所述抗体的组合物及其用途 | |
CN106795222A (zh) | 用结合集落刺激因子1受体(csf1r)的抗体治疗病状的方法 | |
TWI654996B (zh) | 微核糖核酸let-7及轉形生長因子β第三類受體調控軸作為心臟損傷標的之用途 | |
CN102548573A (zh) | Nkg2d抑制剂在治疗心血管和代谢疾病如2型糖尿病中的用途 | |
CN103237812A (zh) | Ephrin B2抗体及其应用 | |
CN106661105A (zh) | 用il‑20拮抗剂治疗炎性疼痛 | |
RU2741802C2 (ru) | АНТИТЕЛО К Myl9 | |
EP3490675A1 (en) | Gamma delta t cells as a target for treatment of solid tumors | |
US9221904B2 (en) | Treatment of osteoarthritis using IL-20 antagonists | |
CN102170910A (zh) | 糖链识别受体的新用途 | |
EP3426677B1 (en) | Use of pneumolysin peptides as antagonists against toll-like receptor 4 and methods of treating toll-like receptor 4 related diseases | |
US9982043B2 (en) | Use of IL-20 antagonists for treating pancreatic cancer | |
KR20210153039A (ko) | 커넥신 43 항체 및 이의 용도 | |
CN107278207A (zh) | 用于治疗转移性疾病的rankl特异性试剂 | |
US20200024347A1 (en) | Or10h1 antigen binding proteins and uses thereof | |
TWI675042B (zh) | 結合至犬血管內皮生長因子的抗體及其用於治療犬血管新生相關疾病之用途 | |
US9751949B2 (en) | Method of inhibiting adipogenesis with an IL-20 antibody | |
TWI726228B (zh) | Cd14拮抗分子用於治療癌症 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent for invention or patent application | ||
CI01 | Correction of invention patent gazette |
Correction item: Applicant Correct: National Cheng Kung University False: National Cheng Kung University Number: 33 Volume: 31 |
|
CI02 | Correction of invention patent application |
Correction item: Applicant Correct: National Cheng Kung University False: National Cheng Kung University Number: 33 Page: The title page Volume: 31 |
|
ERR | Gazette correction | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200320 Address after: Tainan City, Taiwan, China Patentee after: Yongfu Biotechnology Co., Ltd Address before: Taiwan, China Tainan University Road, No. 1 Co-patentee before: Zhang Mingxi Patentee before: NATIONAL CHENG KUNG University |